Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Thyroid Cell
Therapeutic Area : Endocrinology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sernova Submits IND for Cell Pouch Bio-Hybrid Organ in Hypothyroidism
Details : Company’s Cell Pouch auto-transplanted with thyroid cells is being investigated for nodular thyroid disease. It restores thyroxine and triiodothyronine, to pre-thyroidectomy levels.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 03, 2025
Lead Product(s) : Thyroid Cell
Therapeutic Area : Endocrinology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Donor Islet Cell,Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Evotec
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sernova’s Cell Pouch System™ (human donor islets cell) is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells.
Product Name : Sernova Cell Pouch
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 01, 2023
Lead Product(s) : Human Donor Islet Cell,Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Evotec
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Donor Islet Cell,Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sernova’s Cell Pouch System™ (human donor islets cell) is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells.
Product Name : Sernova Cell Pouch
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 03, 2023
Lead Product(s) : Human Donor Islet Cell,Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, AstraZeneca will explore the use of Sernova’s Cell Pouch System as a potential platform for integration with its development of the next wave of innovative cell therapies for various indications.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 05, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : AstraZeneca
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Human Donor Islet Cell
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sernova’s Cell Pouch System is a novel implant consisting human islets cells, which allows for reestablishment of production of triiodothyronine (T3) and thyroxine (T4) and the hypothalamic-pituitary-thyroid axis, to preserve thyroid function following...
Product Name : Sernova Cell Pouch
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 30, 2023
Lead Product(s) : Human Donor Islet Cell
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Donor Islet Cell
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Human Donor Islets Cell are transplanted into the Sernova Cell Pouch approximately six weeks after Cell Pouch implantation to allow development of fully vascularized native tissue chambers and achieve a stable immunosuppressant regimen.
Product Name : Sernova Cell Pouch
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 17, 2022
Lead Product(s) : Human Donor Islet Cell
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Donor Islet Cell
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Cell Pouch is implantable device, that is transplanted with therapeutic cells such as Sernova Cell Pouch (insulin producing islets). Combination product is designed for treatment of Type 1 Diabetes Mellitus with hypoglycemia.
Product Name : Sernova Cell Pouch
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 11, 2022
Lead Product(s) : Human Donor Islet Cell
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Human Donor Islet Cell,Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Evotec
Deal Size : $270.0 million
Deal Type : Financing
Details : Sernova will use the net proceeds from the common shares for general working capital purposes and to continue pursuing ‘functional cures’ for diabetes, hypothyroidism and hemophilia A by using Human donor islets cell (Sernova Cell Pouch).
Product Name : Sernova Cell Pouch
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 09, 2022
Lead Product(s) : Human Donor Islet Cell,Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Evotec
Deal Size : $270.0 million
Deal Type : Financing